Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 6.25 6.00 6.50 6.25 6.25 6.25 30,370 07:45:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18.3 -12.0 -1.8 - 45

Yourgene Health PLC Earn-out Milestone, Issue of Equity & TVR

11/08/2021 7:01am

UK Regulatory (RNS & others)


Yourgene Health (LSE:YGEN)
Historical Stock Chart


From Jul 2021 to Jul 2022

Click Here for more Yourgene Health Charts.

TIDMYGEN

RNS Number : 2238I

Yourgene Health PLC

11 August 2021

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Earn-out Milestone, Issue of Equity & Total Voting Rights

Manchester, UK 11 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces an issue of equity pursuant to the terms of the acquisition of Coastal(R) Genomics Inc. ("Coastal") which completed in August 2020 (the "Acquisition").

Under the terms of the Coastal acquisition, a second strategic partnership Coastal Genomics' Ranger(R) technology was announced on 21 June 2021 which met the criteria for a Qualifying Commercial Agreement with a Strategic Partner, triggering the second and final equity earn-out milestone arising from the Acquisition. The first equity earn-out milestone was announced in March 2021 with the resultant shares issued on 12 April 2021.

To satisfy the Acquisition terms, the achievement of this second milestone gives rise to the issuance of 4,880,971 new shares in the Company's wholly owned subsidiary, Yourgene Health Canada Investment Ltd ("YGEN-HCIL"), to the former shareholders of Coastal. These YGEN-HCIL shares are exchangeable on a one-for-one basis with the Company's ordinary shares, subject to certain lock-in provisions over the next one to five years.

In addition to the above issue of YGEN-HCIL shares, 85,124 new ordinary shares in the Company will be issued to a US-based individual, who has elected to receive his earn-out payment in this form. Application will be made to the London Stock Exchange to admit the 85,124 new ordinary to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 16 August 2021. The new ordinary shares will rank pari passu with the existing ordinary shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of Company shares detailed above the enlarged issued share capital of the Company will comprise 723,780,306 ordinary shares of 0.1p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

In addition, as a result of the issuance of the YGEN-HCIL shares detailed above there are now a total of 19,826,660 unlisted YGEN-HCIL shares issued which are exchangeable on a one-for-one basis for the Company's shares as described above.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                    Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                                investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                   Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
Singer Capital Markets (Joint Corporate                                Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                  Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor         Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                         Mob: 07980 541 893 / Mob: 07584 391 303 
 
 
 

About Yourgene Health plc

Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.

Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger(R) Technology, the Yourgene LightBench(R) and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.

Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on LinkedIn and Twitter .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPMMLTMTIBBLB

(END) Dow Jones Newswires

August 11, 2021 02:01 ET (06:01 GMT)

1 Year Yourgene Health Chart

1 Year Yourgene Health Chart

1 Month Yourgene Health Chart

1 Month Yourgene Health Chart
ADVFN Advertorial
Your Recent History
LSE
YGEN
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220701 19:09:15